Trending
- Abu Dhabi radiates optimism as over 300 startups join AIM Congress 2024
- TLcom Capital Raises $154 million in Funding to Boost Its African Growth
- Africa’s $824Bn debt, resource-backed opaque loans slowing growth — AfDB
- LB Investment brings $1.2 trillion portfolio display to AIM Congress spotlight
- AmCham Summit kicks off, setting course for robust future of US-East Africa trade ties
- Why the UN is raising the red flag on the UK-Rwanda asylum treaty
- Portugal’s Galp Energia projects 10 billion barrels in Namibia’s new oil find
- Wärtsilä Energy offers tips on how Africa can navigate energy transition and grid reliability
Browsing: Manufacturing of Candidate COVID-19
COVID-19 Vaccine On African Soil
South African Aspen Pharmacare, a wholly-owned subsidiary of Aspen Holdings, has entered into an arrangement with Janssen Pharmaceutical, an arm of Johnson & Johnson, for the commercial reproduction of candidate COVID vaccine Ad26.COV2-S.
Aspen Pharmacare will do the formulation, filling as well as secondary packaging of the vaccine. After which it will be supplied to Johnson & Johnson.
COVID-19 Vaccine
The fine print of the agreement, including the terms of manufacturing, is yet to be concluded. Further, the technology transfer required to complete the successful implementation of the deal has not yet been finalized.
The manufacturing will be done at one of Aspen Pharmacare’s sterile facilities, which has the capacity to produce 300 million doses per annum, located in Port Elizabeth, South Africa.
Currency, the proposed vaccine is undergoing clinical trials.
To date, Aspen has poured in over $3 million of investment to prepare the …